Back
Back
Back

Annual Conference Schedule

Please join Acella Pharmaceuticals for the following conferences and register to attend one of our product theaters highlighting NP Thyroid®.

February

Nurse Practitioner Associates for Continuing Education
(NPACE)

February 27 - March 2 – Savannah, GA

Attendance: In-Person

April

Nurse Practiotioner Associates for Continuing Education

April 29-26 – Denver, CO

Attendance: In-person

May

American Academy of Physician Associates
(AAPA)

May 20-27 – Nashville, TN

Attendance: TBD

June

Endocrine Society

June 15-18 – Chicago, IL

Attendance: TBD

Product Theater

Thursday, June 15 at 12:30-1:30 pm CT
with Speaker TBD

Title

Coming Soon

American Association of Nurse Practitioners
(AANP)

June 20-25 – New Orleans, LA

Attendance: TBD

Product Theater

Date and
Speaker TBD

Title

Coming Soon

Nurse Practitioner Associates for Continuing Education
(NPACE)

June 28-30 – Boston, MA

Attendance: TBD

July

National Nurse Practitioner Symposium
(NNPS)

July 20-23 – Keystone, CO

Attendance: TBD

Product Theater

Thursday, July 20 at 11:30 am - 1:00 pm MT
with Speaker TBD

Title

Coming Soon

August

Florida Nurse Practitioner Network
(FNP)

August 24-26 – Orlando, FL

Attendance: TBD

Product Theater

Friday, August 25
with Speaker TBD

Title

Coming Soon

Western Endocrine Association
(WEA)

Aug 25-27 – Sedona, AZ

Attendance: TBD

September

American Thyroid Association
(ATA)

September 27 - October 1 – Washington, DC

Attendance: TBD

Product Theater

Date and
Speaker TBD

Title

Coming Soon

North American Menopause Society
(NAMS)

September 27-30 – Philadelphia, PA

Attendance: TBD

Texas Nurse Practitioner Conference
(TNP)

September 28 - October 1 – Dallas, TX

Attendance: In-person

Product Theater

Date and
Speaker TBD

Title

Coming Soon

October

MEDS Fall

October 12–14 – Orlando, FL

Attendance: In-Person

Family Medicine Experience
(FMX)

October 26-30 – Chicago, IL

Attendance: In-person

Nurse Practitioners in Women's Health
(NPWH)

October 29 - November 1 – San Diego, CA

Attendance: In-person

Product Theater

Monday, October 30
with Speaker TBD

Title

Coming Soon

December

American Academy of Anti-Aging Medicine
(A4M)

December 14-16 – Las Vegas, NV

Attendance: In-person

INDICATIONS & IMPORTANT RISK INFORMATION INCLUDING BLACK BOX WARNING
Important Risk Information

Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
  • NP Thyroid® is contraindicated in patients with uncorrected adrenal insufficiency, untreated thyrotoxicosis, and hypersensitivity to any component of the product.
  • In the elderly and in patients with cardiovascular disease, NP Thyroid® should be used with greater caution than younger patients or those without cardiovascular disease.
  • Use of NP Thyroid® in patients with diabetes mellitus or adrenal cortical insufficiency may worsen the intensity of their symptoms.
  • The therapy of myxedema coma requires simultaneous administration of glucocorticoids.
  • Concomitant use of NP Thyroid® with oral anticoagulants alters the sensitivity of oral anticoagulants. Prothrombin time should be closely monitored in thyroid-treated patients on oral anticoagulants.
  • In infants, excessive doses of NP Thyroid® may produce craniosynostosis.
  • Partial loss of hair may be experienced by children in the first few months of therapy but is usually transient.
  • Adverse reactions associated with NP Thyroid® therapy are primarily those of hyperthyroidism due to therapeutic overdosage.
  • Many drugs and some laboratory tests may alter the therapeutic response to NP Thyroid®. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Administer at least 4 hours before or after drugs that are known to interfere with absorption. Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption.
  • NP Thyroid® should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated.

Indication

NP Thyroid® (thyroid tablets, USP) is a prescription medicine that is used to treat a condition called hypothyroidism from any cause, except for cases of temporary hypothyroidism, which is usually associated with an inflammation of the thyroid (thyroiditis). It is meant to replace or supplement a hormone that is usually made by your thyroid gland.

NP Thyroid® is also used in the treatment and prevention of normal functioning thyroid goiters, such as thyroid nodules, Hashimoto’s thyroiditis, multinodular goiter, and in the management of thyroid cancer.